BACKGROUND: Accelerated @entity604 is a well-recognized complication after cardiac transplantation (HTx) due to immunosuppressive therapy. The purpose of this prospective, longitudinal, randomized, placebo-controlled, double-blind study was to investigate the effect of @entity3873 ( @entity3873 ) in the prevention of @entity604 and @entity174 rate after HTx. METHODS: Basic therapy included 1000 mg of @entity460 daily and sex hormone replacement in hypogonadal @entity1 . A total of 132 @entity1 (111 male, 21 female; mean age: 51+/-10 years; 35+/-25 months after HTx) were randomized to 0.25 microg of @entity3873 or placebo. @entity79 ( @entity79 , g/cm2; T score, %) of the lumbar spine and x-rays for the assessment of vertebral @entity174 were performed at baseline and after 12, 24, and 36 months. Biochemical indexes of mineral metabolism were measured every 3 months. RESULTS: Overall @entity79 was significantly decreased after HTx (T score 87+/-13%). @entity79 increased continuously within the study period in the @entity3873 group (1 year: 2.2+/-4.8%; 2 years: 3.9+/-5.4%; 3 years: 5.7+/-4.4%) as well as in the placebo group (1 year: 1.8+/-4.9%; 2 years: 3.7+/-6.5%; 3 years: 6.1+/-7.8%) without statistical difference between the groups. @entity174 incidence was low during the study interval (1 year: 2.0%; 2 years: 3.4%; 3 years: 0%). @entity6126 (20%) was associated with a lower @entity79 (78+/-12% vs. 88+/-12%; P<0.01) and a higher increase (35%) after hormone replacement in comparison to normogonadal @entity1 . Increased intact parathyroid hormone and bone resorption markers decreased significantly during therapy. CONCLUSIONS: @entity460 supplementation and sex hormone replacement in @entity6126 proved a sufficient long-term prevention therapy to improve decreased @entity79 and to prevent @entity174 after HTx. Besides immunosuppression, both @entity6126 and @entity3528 play a major role in the long-term @entity604 and should therefore be monitored and treated adequately. Low-dose @entity3873 demonstrated no significant extra benefit regarding @entity79 and @entity174 rate in the long-term period after HTx.

Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'Fracture', 'fracture'] @entity3873 :: ('MESH:D002117', 'Chemical') :: ['calcitriol', '1,25-dihydroxyvitamin D3'] @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['secondary hyperparathyroidism'] @entity79 :: ('MESH:D001847', 'Disease') :: ['Bone mineral density', 'BMD'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium'] @entity6126 :: ('MESH:D007006', 'Disease') :: ['concomitant hypogonadism', 'hypogonadism', 'Hypogonadism']
@entity3873 :: (MESH:D002117,Chemical) :: ['calcitriol']
